Taysha Gene Therapies (TSHA) Set to Announce Quarterly Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.1286) per share and revenue of $0.76 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts expect Taysha Gene Therapies to post ($0.52) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $4.01 on Tuesday. The company has a market cap of $1.31 billion, a P/E ratio of -9.55 and a beta of 1.19. The stock has a fifty day moving average price of $4.98 and a 200 day moving average price of $5.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.76 and a quick ratio of 17.76. Taysha Gene Therapies has a 12 month low of $3.45 and a 12 month high of $7.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TSHA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Robert W. Baird increased their price objective on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Finally, Wolfe Research started coverage on shares of Taysha Gene Therapies in a research report on Thursday, September 17th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Taysha Gene Therapies has an average rating of “Buy” and an average target price of $12.77.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.